CCR5Δ32 genotype is associated with outcome in type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 86, Issue 2, 2009, Pages 140-145

  Muntinghe, Friso L H ^a   Gross, Sascha ^a   Bakker, Stephan J L ^a   Landman, Gijs W D ^b   van der Harst, Pim ^a   Bilo, Henk J G ^a,b   Navis, Gerjan ^a   Zuurman, Mike W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

CCR5; CCR5 32; Chemokine; Diabetes; Survival

Indexed keywords

CHEMOKINE RECEPTOR CCR5; INSULIN; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHROMOSOME 3P; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC DIET; FEMALE; FOLLOW UP; GENE DELETION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; SURVIVAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; GENETICS; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; ONSET AGE; OUTPATIENT; STATISTICS; SURVIVOR; TREATMENT OUTCOME;

AGE OF ONSET; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; GENOTYPE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; RECEPTORS, CCR5; SURVIVORS; TREATMENT OUTCOME;

EID: 70349783687     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.08.013     Document Type: Article

References (33)

1. Baggiolini M. Chemokines and leukocyte traffic. Nature 392 6676 (1998) 565-568
2. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 6 (2006) 610-621
3. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., and Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J. Biol. Chem. 272 49 (1997) 30603-30606
4. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 7 (2009) 692-698
5. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 3 (1996) 367-377
6. Raport C.J., Gosling J., Schweickart V.L., Gray P.W., and Charo I.F. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J. Biol. Chem. 271 29 (1996) 17161-17166
7. Wilcox J.N., Nelken N.A., Coughlin S.R., Gordon D., and Schall T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler. Thromb. 1 Suppl 1 (1994) S10-S13
8. Libby P. Inflammation in atherosclerosis. Nature 420 6917 (2002) 868-874
9. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 116 7 (2006) 1793-1801
10. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 11 1 (2006) 36-41
11. Fischereder M., Luckow B., Hocher B., Wuthrich R.P., Rothenpieler U., Schneeberger H., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 357 9270 (2001) 1758-1761
12. Gonzalez P., Alvarez R., Batalla A., Reguero J.R., Alvarez V., Astudillo A., et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2 4 (2001) 191-195
13. Pai J.K., Kraft P., Cannuscio C.C., Manson J.E., Rexrode K.M., Albert C.M., et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 186 1 (2006) 132-139
14. Szalai C., Duba J., Prohaszka Z., Kalina A., Szabo T., Nagy B., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 158 1 (2001) 233-239
15. Muntinghe F., Verduijn M., Zuurman M., Grootendorst D., Carrero J.J., Quershi A.R., et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J. Am. Soc. Nephrol. 20 (2009) 1641-1649
16. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 4 (1998) 229-234
17. Kleefstra N., Ubink-Veltmaat L.J., Houweling S.T., Groenier K.H., Meyboom-de Jong B., and Bilo H.J. Cross-sectional relationship between glycaemic control, hyperglycaemic symptoms and quality of life in type 2 diabetes (ZODIAC-2). Neth. J. Med. 63 6 (2005) 215-221
18. Manjunath G., Sarnak M.J., and Levey A.S. Prediction equations to estimate glomerular filtration rate: an update. Curr. Opin. Nephrol. Hypertens. 10 6 (2001) 785-792
19. Clark V.J., Metheny N., Dean M., and Peterson R.J. Statistical estimation and pedigree analysis of CCR2-CCR5 haplotypes. Hum. Genet. 108 6 (2001) 484-493
20. Potteaux S., Combadiere C., Esposito B., Lecureuil C., it-Oufella H., Merval R., et al. Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26 8 (2006) 1858-1863
21. Veillard N.R., Kwak B., Pelli G., Mulhaupt F., James R.W., Proudfoot A.E., et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 94 2 (2004) 253-261
22. Zernecke A., Liehn E.A., Gao J.L., Kuziel W.A., Murphy P.M., and Weber C. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 107 11 (2006) 4240-4243
23. Pokorny V., McQueen F., Yeoman S., Merriman M., Merriman A., Harrison A., et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann. Rheum. Dis. 64 3 (2005) 487-490
24. Dytfeld J., Bogdanski P., Pupek-Musialik D., Jagodzinski P.P., Bryl W., and Kujawa A. [Expression of chemokine receptor CCR5 in patients with type 2 diabetes]. Pol. Merkur. Lekarski. 20 116 (2006) 195-198
25. Cavusoglu E., Eng C., Chopra V., Clark L.T., Pinsky D.J., and Marmur J.D. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler. Thromb. Vasc. Biol. 27 4 (2007) 929-935
26. Boger C.A., Fischereder M., Deinzer M., Aslanidis C., Schmitz G., Stubanus M., et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 183 1 (2005) 121-129
27. Nakajima K., Tanaka Y., Nomiyama T., Ogihara T., Piao L., Sakai K., et al. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes 51 1 (2002) 238-242
28. Prasad P., Tiwari A.K., Kumar K.M., Ammini A.C., Gupta A., Gupta R., et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med. Genet. 8 (2007) 20
29. Schober A., Manka D., von Hundelshausen P., Huo Y., Hanrath P., Sarembock I.J., et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106 12 (2002) 1523-1529
30. van Wanrooij E.J., Happe H., Hauer A.D., de Vos P., Imanishi T., Fujiwara H., et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25 12 (2005) 2642-2647
31. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11 11 (2005) 1170-1172
32. Kanters S.D., Banga J.D., Stolk R.P., and Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc. Med. 4 2 (1999) 67-75
33. Jager K.J., Zoccali C., Macleod A., and Dekker F.W. Confounding: what it is and how to deal with it. Kidney Int. 73 3 (2008) 256-260